Testosterone Cypionate Medicare Part D Coverage

Why Medicare Part D Covers Testosterone Cypionate

Medicare Part D includes testosterone cypionate on most plan formularies because the FDA approved injectable testosterone cypionate for male hypogonadism decades ago, and it remains one of the most prescribed forms of testosterone replacement therapy (TRT) in the United States [1]. The Endocrine Society's 2018 clinical practice guideline recommends injectable testosterone cypionate as a first-line treatment for men with confirmed testosterone deficiency [2].

How Formulary Placement Works

Part D formularies typically sort drugs into tiers. Generic testosterone cypionate usually sits on Tier 2 (preferred generic) or Tier 3 (preferred brand), depending on the plan's pharmacy benefit manager negotiations. Tier placement directly controls your copay. A Tier 2 placement in a standard 2026 Part D plan means a copay between $10 and $25, while Tier 3 can push that to $30 to $45 [3].

Why Generic Status Matters for Cost

Because multiple manufacturers produce generic testosterone cypionate, competition holds wholesale prices well below branded alternatives like Aveed (testosterone undecanoate) or Xyosted (testosterone enanthate autoinjector). The FDA's Orange Book lists several approved ANDA holders for testosterone cypionate injection [4]. This generic competition is one reason Part D plans favor it over newer branded injectables that can cost $500 or more per month.

Prior Authorization and Step Therapy Requirements

Roughly 70% of Part D plans require prior authorization before they will cover testosterone cypionate. This is not a denial. It is a documentation checkpoint. The AUA/Endocrine Society guidelines define male hypogonadism as a total testosterone concentration below 300 ng/dL (10.4 nmol/L) confirmed on two separate morning samples [2].

What Your Prescriber Must Submit

Your doctor's office will submit a prior authorization form showing:

• Two morning total testosterone levels below 300 ng/dL drawn before 10 AM
• Symptoms consistent with hypogonadism (fatigue, decreased libido, reduced muscle mass, depressed mood)
• The absence of reversible causes such as opioid use, uncontrolled sleep apnea, or pituitary pathology
• An ICD-10 code of E29.1 (testicular hypofunction)

The Endocrine Society guideline specifically recommends against prescribing testosterone to men whose low levels are explained by reversible illness or medication effects [2].

Step Therapy Policies

Some Part D plans impose step therapy, requiring a trial of topical testosterone (gel or patch) before approving injectables. If you experience skin irritation, inadequate absorption, or transfer risk concerns with topical formulations, your prescriber can request a step-therapy override. A 2017 analysis in the Journal of Clinical Endocrinology & Metabolism documented that injectable testosterone produced more consistent serum levels compared to transdermal options in many patients [5].

What You Pay at Each Coverage Phase

Medicare Part D has four coverage phases in 2026, and your testosterone cypionate cost shifts at each stage. Understanding these phases prevents billing surprises.

Initial Deductible Phase

The 2026 Part D standard deductible is $590. Until you meet that amount, you pay the full negotiated price for testosterone cypionate, which typically ranges from $30 to $80 per vial depending on the pharmacy. Some plans waive the deductible for Tier 1 and Tier 2 drugs, so check your plan's Evidence of Coverage document [3].

Initial Coverage Phase

After meeting the deductible, you enter the initial coverage phase. Here you pay your plan's set copay or coinsurance. For generic testosterone cypionate on Tier 2, expect $10 to $25 per fill. Tier 3 placement means $25 to $45. This phase lasts until your combined out-of-pocket plus plan-paid costs reach the initial coverage limit of $5,030 in 2026 [3].

Coverage Gap (Donut Hole)

The Inflation Reduction Act capped Part D out-of-pocket spending, and the manufacturer discount program means you pay 25% of the negotiated price for generic drugs in the gap. For a testosterone cypionate vial with a plan-negotiated price of $60, that means approximately $15 out of pocket during this phase [6].

Catastrophic Coverage

Once your true out-of-pocket spending hits $2,000 (the 2026 cap established by the Inflation Reduction Act provisions for Part D), you pay nothing additional for covered Part D drugs for the rest of the year [6]. This cap is a significant change from pre-2025 rules and directly benefits men on ongoing TRT.

How to Reduce Your Testosterone Cypionate Costs

Even with Part D coverage, several strategies can lower your total annual TRT expense.

Medicare Extra Help (Low-Income Subsidy)

The Medicare Extra Help program reduces Part D premiums, deductibles, and copays for enrollees with limited income and resources. If you qualify for full Extra Help in 2026, your testosterone cypionate copay drops to $4.50 for generic drugs or $11.20 for brand-name drugs [7]. The Social Security Administration handles applications.

Comparing Part D Plans During Open Enrollment

Plan formularies change every year. A plan that placed testosterone cypionate on Tier 2 in 2025 may move it to Tier 3 in 2026. Use the Medicare Plan Finder tool at medicare.gov during the Annual Enrollment Period (October 15 through December 7) to compare copays, tier placements, and pharmacy networks for your specific medication and zip code [3].

Cash-Pay and GoodRx as a Backup

When your plan's negotiated price exceeds the cash-pay price, you can choose to pay cash instead of using your Part D benefit. The average cash price for a 200 mg/mL, 10 mL testosterone cypionate vial is around $60 at major chain pharmacies [8]. Paying cash does not count toward your Part D deductible or out-of-pocket maximum, so weigh the tradeoff carefully.

90-Day Fills and Mail-Order Pharmacies

Most Part D plans offer lower per-unit costs for 90-day supplies through preferred mail-order pharmacies. If your testosterone cypionate dose is stable, switching to 90-day fills could reduce your annual copay by 20% to 30% compared to monthly fills [3].

Clinical Monitoring Medicare Covers Alongside TRT

Medicare Part B and Part D together cover the monitoring labs your prescriber should order during TRT. The Endocrine Society guideline recommends checking total testosterone, hematocrit, and PSA at baseline, 3 to 6 months after starting therapy, and then annually [2].

Required Lab Tests

• Total testosterone (trough level): drawn the morning before your next injection. Target range: 400 to 700 ng/dL for most men on TRT [2].
• Complete blood count with hematocrit: testosterone stimulates erythropoiesis. Hematocrit above 54% requires dose reduction or temporary cessation. A 2010 meta-analysis in JAMA identified polycythemia as the most common adverse effect of testosterone therapy [9].
• PSA (prostate-specific antigen): baseline and follow-up. The AUA guideline on testosterone therapy recommends against starting TRT when baseline PSA exceeds 4 ng/mL without urological evaluation [10].
• Lipid panel: testosterone affects HDL and LDL. The Endocrine Society recommends periodic lipid monitoring, though the TRAVERSE trial (N=5,246) showed no significant increase in major adverse cardiovascular events with testosterone versus placebo over a mean follow-up of 33 months [11].

The TRAVERSE Trial and Cardiovascular Safety

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was the first large randomized controlled trial powered to assess cardiovascular safety of TRT. Among 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease, testosterone 1.62% gel did not increase the incidence of major adverse cardiovascular events (hazard ratio 0.99; 95% CI 0.81 to 1.21) [11]. This trial changed the risk-benefit conversation for older men considering TRT, including those on Medicare.

A secondary TRAVERSE analysis published in JAMA found that testosterone treatment was associated with greater progression of coronary artery plaque volume compared to placebo, though this did not translate to more clinical events [12]. Your prescriber should discuss both findings with you.

Branded vs. Compounded Testosterone: What Part D Covers

Medicare Part D generally does not cover compounded medications from 503A pharmacies. Compounded testosterone cypionate from a 503B outsourcing facility may be covered if it appears on the plan's formulary, though this is uncommon [13].

Branded Injectable Alternatives

Branded testosterone products like Aveed (testosterone undecanoate, given every 10 weeks by a clinician) are covered by some Part D plans but frequently sit on Tier 4 or Tier 5 with specialty copays of $100 to $300 per injection. The FDA label for Aveed includes a REMS program due to risks of pulmonary oil microembolism and anaphylaxis [14].

When Compounding Makes Sense

If you need a concentration or preservative-free formulation not available commercially, a compounded product from a 503B facility may be appropriate. Expect to pay approximately $80 per month out of pocket. The FDA's page on 503B outsourcing facilities explains the regulatory distinction between 503A and 503B compounding [15].

Special Considerations for Medicare Beneficiaries Over 65

Men over 65 represent a growing proportion of TRT users. A 2023 cross-sectional study in the Journal of Urology found that testosterone prescriptions among men 65 and older increased by 50% between 2015 and 2021 [16]. Medicare coverage makes this trend financially feasible, but clinical caution applies.

Age-Specific Monitoring

The Endocrine Society recommends that men over 65 undergo DXA bone density scans at baseline if starting TRT for osteoporosis prevention, since testosterone deficiency is a recognized cause of secondary osteoporosis in men [2]. Medicare Part B covers DXA scans every 24 months for qualifying beneficiaries.

Prostate Screening Coordination

Before initiating TRT, men over 65 should have a baseline PSA and digital rectal exam. The USPSTF recommendation on prostate cancer screening advises shared decision-making for men aged 55 to 69, noting that PSA-based screening has a small net benefit in this age group [17]. For men on TRT, serial PSA monitoring becomes even more relevant.

How to File a Part D Coverage Appeal

If your Part D plan denies testosterone cypionate coverage, you have the right to appeal.

Standard Appeal Process

1. Ask your prescriber to submit a coverage determination request with clinical documentation.
2. If denied, file a redetermination within 60 days.
3. If still denied, request an Independent Review Entity (IRE) review.
4. The full appeals process is outlined at medicare.gov [3].

Exception Requests

You can also request a formulary exception or tier exception. A tier exception asks the plan to cover testosterone cypionate at a lower copay tier. A formulary exception requests coverage when the drug is not on the plan's formulary at all. Both require a supporting statement from your prescriber explaining medical necessity [3].